# A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

> **NCT05815485** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The University of Texas Medical Branch, Galveston** · enrollment: 144 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Azeliragon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05815485
- **Lead sponsor:** The University of Texas Medical Branch, Galveston
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-04
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815485, "A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05815485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*